Safety and Tolerability of Thrombin Inhibition in Scleroderma-Associated Interstitial Lung Disease.

ABSTRACT:

Objective

Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc) (scleroderma) and the leading cause of scleroderma-related deaths. There exists an unmet need for a new drug therapy for ILD-complicated SSc. Substantial evidence supports an important role for thrombin in the pathogenesis of SSc-associated ILD (hereafter SSc-ILD), and targeting thrombin with a direct thrombin inhibitor could prove to be a novel and effective treatment strategy. As a first step toward designing a clinical trial to test the efficacy of thrombin inhibition in SSc-ILD, we conducted this study to test the safety and tolerability of dabigatran in patients with SSc-ILD.

Methods

We performed a prospective, single-center, open-label treatment trial with the direct thromb

SUBMITTER: Silver RM 

PROVIDER: S-EPMC6858036 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature